Creating the Next Generation of Targeted Cancer Therapies

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. We are developing proprietary drugs independently and through research and development collaborations with a core objective to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. Our PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and we plan to develop PDCs independently and through research and development collaborations.

A Multi-Asset Product Portfolio of Chemotherapeutics

We employ a drug discovery and development approach that allows us to efficiently design and develop drug candidates rapidly. In just a couple of years, we have successfully advanced our lead PDC, iopofosine into multiple Phase 1 and 2 clinical studies in ten different cancers including a pivotal study for Waldenstrom’s macroglobulinemia. Additionally, we have five rapidly progressing proprietary preclinical programs utilizing different payloads and have established several strategic collaborations.

Explore Our Pipeline

Advancing Innovation in Targeted Therapies

Drug conjugate approaches have faced many challenges, including limited to no improvement in toxicities and clinical efficacy. These issues can often be traced back to the mechanism used to target the tumor cells. Understanding this challenge, Cellectar has taken a novel approach to pursue a means of targeting cancers in a manner that takes advantage of the increased metabolic needs of all cancers and allows our compounds to gain entry directly into the tumor cell’s cytoplasm. In order to satisfy its increased metabolism, tumor cells change regions on the cell surface, these changes in the cell surface are what our PLEs target. These changes are unique to tumor cells and does not occur in highly metabolic normal cells. Importantly, because nearly all tumor cells and all tumor types have increased metabolic needs, our molecules can target the primary tumor, any metastatic tissue and the cancer stem cells regardless of the tumor type or location.

View Our Technology

QUESTIONS?

Contact Us

Upcoming Events

2022 Annual Meeting of Stockholders

View All Events

Latest Presentation

Corporate Presentation - June 2022
July 1, 2022
Download now

Leadership

"The growth and development of people is the highest calling of leadership."

– Jim Caruso
President and CEO

View Leadership

IR Contact Information

Company Information

Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
investors@cellectar.com

Investor Relations

LifeSci Advisors
Monique Kosse
Managing Director
T: 212-915-3820
monique@lifesciadvisors.com

Social Media

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.